AMPA Modulators (Ampakines)

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Indications

Primary Indications

Major depressive disorder (including treatment-resistant cohorts)Cognitive impairment associated with psychiatric or neurologic diseaseSchizophrenia—negative and cognitive symptomsAttention and vigilance deficits (investigational)

Mechanism

AMPA modulators bind allosteric sites on AMPA receptors to slow desensitization and/or deactivation, amplifying glutamatergic synaptic currents. This facilitation enhances LTP, increases cortical excitation in a controlled manner, and can upregulate BDNF and related plasticity pathways. Therapeutically, this may translate to faster-acting antidepressant effects, pro-cognitive benefits, and improvement in negative symptoms.

Protocol

Preparation

Medical and psychiatric screening, medication review, and baseline cognitive/clinical assessments. Discuss sleep, caffeine, and seizure risk.

Procedure

Oral dosing according to study protocol (fixed or titrated)
Regular monitoring of vitals and adverse effects
Scheduled cognitive and clinical outcome assessments
Concomitant psychotherapy optional/condition-specific

Frequency: Once or twice daily dosing in most protocols

Duration: 2–12 weeks typical in trials; may vary by compound and endpoint

Total Treatment Time: Study-defined; includes screening, treatment, and follow-up phases

Equipment

Standard clinical monitoring (blood pressure, pulse)
Cognitive testing tools (computerized batteries or neuropsychological tests)
ECG as indicated by protocol
Electronic diaries for symptom tracking (optional)

Session Structure

Pre-Session

Baseline vitals, symptom scales, cognitive test battery

Post-Session

Final evaluation, taper or stop per protocol, and safety follow-up

Expected Outcomes

Immediate

Possible mild activation/alertness
Headache or GI discomfort (some patients)

Short Term

Improved attention/vigilance
Faster information processing
Early mood lift in responders

Long Term

Sustained cognitive benefits (subset)
Reduced depressive symptoms (subset)
Functional improvements in daily tasks

Side Effects

common

Headache
Insomnia or sleep disturbance
Anxiety/activation
Nausea
Dizziness

uncommon

Elevated blood pressure or heart rate
Irritability
Appetite suppression

rare

Seizure in predisposed individuals
Clinically significant hypertension
Arrhythmia

Contraindications

absolute

Active seizure disorder
Known hypersensitivity to study compound

relative

History of epilepsy in first-degree relatives
Uncontrolled cardiovascular disease
Severe insomnia or agitation at baseline

special considerations

Caution with drugs that lower seizure threshold (e.g., certain antidepressants/antipsychotics at high doses)
Careful dosing in older adults with polypharmacy

Patient Selection

ideal candidates

Adults with cognitive complaints related to psychiatric illness
Patients with depression seeking alternatives to monoaminergic agents
Individuals with schizophrenia experiencing cognitive/negative symptoms despite stable antipsychotic therapy

screening required

Clinical interview and structured diagnostic assessment
Medication reconciliation and seizure risk assessment
Baseline vitals, labs per protocol, and optional ECG

Training Requirements

practitioner

Experience with investigational psychopharmacology
Competence in monitoring stimulation-related side effects and sleep issues
Ability to administer and interpret cognitive assessments

facility

Capability for regular safety monitoring
Emergency response protocols
Secure investigational drug storage and accountability

Research Evidence

Key Studies

BIIB104 (PF-04958242): AMPA PAM studied for cognitive impairment in schizophrenia; early-phase signals on cognition.
TAK-653: AMPA receptor potentiator with exploratory antidepressant and cognitive findings in early trials.
CX-series (e.g., CX-717, CX-1739): historical ampakines studied for cognition, vigilance, and respiratory drive; mixed efficacy and regulatory outcomes.
ORG-26576: investigated for mood/cognition endpoints; variable results.

Limitations

Heterogeneous compounds and targets; mixed efficacy across indications; limited large Phase III data; seizure threshold concerns necessitate careful selection.

Cost Considerations

typical session cost: Not applicable outside trials; may incur study visit costs if not covered

total treatment cost: Trial-dependent; investigational drug typically provided in research

insurance coverage: Not covered; investigational use only

cost effectiveness: Unknown pending definitive efficacy data

ux display: undefined

collapsible: undefined

heading: undefined

Integration Support

Concurrent Therapies

Cognitive remediation or rehabilitation programs
Evidence-based psychotherapy (CBT, ACT) for mood symptoms
Psychoeducation and skills training for schizophrenia

Special Populations

👶Pregnancy

Contraindicated in investigational context unless a specific protocol exists

Clinical Notes

Screen carefully for seizure risk and baseline insomnia/anxiety.
Consider morning dosing to reduce sleep disruption.
Track cognition with validated, reliable measures to detect signal.
Manage expectations—benefits appear variable between compounds and individuals.

This treatment information is for educational purposes only. Treatment decisions should be made in consultation with qualified healthcare professionals based on individual circumstances, symptoms, and medical history. Do not attempt treatment without professional guidance.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists